Iovance Biotherapeutics Inc

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. Our lead, late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer.

Iovance Cell Therapy Center
Located in Philadelphia, PA, the Iovance Cell Therapy Center (iCTC) is the first centralized and scalable manufacturing facility dedicated to producing tumor infiltrating lymphocytes (TIL) as a potential therapy for patients with solid tumors.

The National Cancer Institute (NCI) and other academic centers have historically manufactured tumor infiltrating lymphocyte (TIL) therapies for research purposes. To date, these site-specific processes have not been scalable or standardized to serve sizeable patient populations. Iovance was founded to deliver broad access to TIL therapy for people with cancer by developing clinical trials and centralized, scalable manufacturing processes to enable regulatory approvals and commercial launches.

We established our leadership within T-cell-based immunotherapy by building and augmenting the patent rights for our proprietary tumor infiltrating lymphocyte (TIL) technology platform—developed internally and licensed from third parties.